1. Practical instructions for using drugs in CT and MR cardiac imaging
- Author
-
Rovere, G., Meduri, A., Savino, G., Flammia, F. C., Lo Piccolo, F., Carafa, M. R. P., Larici, A. R., Natale, L., Merlino, B., Marano, R., Rovere G., Meduri A. (ORCID:0000-0003-2332-6428), Savino G., Flammia F. C., Lo Piccolo F., Carafa M. R. P., Larici A. R. (ORCID:0000-0002-1882-6244), Natale L. (ORCID:0000-0002-7949-5119), Merlino B. (ORCID:0000-0003-1104-3463), Marano R. (ORCID:0000-0003-2710-2093), Rovere, G., Meduri, A., Savino, G., Flammia, F. C., Lo Piccolo, F., Carafa, M. R. P., Larici, A. R., Natale, L., Merlino, B., Marano, R., Rovere G., Meduri A. (ORCID:0000-0003-2332-6428), Savino G., Flammia F. C., Lo Piccolo F., Carafa M. R. P., Larici A. R. (ORCID:0000-0002-1882-6244), Natale L. (ORCID:0000-0002-7949-5119), Merlino B. (ORCID:0000-0003-1104-3463), and Marano R. (ORCID:0000-0003-2710-2093)
- Abstract
The progressive increase in numbers of noninvasive cardiac imaging examinations broadens the spectrum of knowledge radiologists are expected to acquire in the management of drugs during CT coronary angiography (CTCA) and cardiac MR (CMR) to improve image quality for optimal visualization and assessment of the coronary arteries and adequate MR functional analysis. Aim of this review is to provide an overview on different class of drugs (nitrate, beta-blockers, ivabradine, anxiolytic, adenosine, dobutamine, atropine, dipyridamole and regadenoson) that can be used in CTCA and CMR, illustrating their main indications, contraindications, efficacy, mechanism of action, metabolism, safety, side effects or complications, and providing advices in their use.
- Published
- 2021